Direct-acting antivirals for chronic hepatitis C treatment: The experience of two tertiary university centers in Brazil

Table 1 Characteristics of patients with hepatitis C virus (n = 532)

	HCV patients (n = 532), % (n) or mean ± SD
Age (yr)	56.88 ± 11.08
Men/women	51.1% (272)/48.9% (260)
High-blood pressure	44.1% (231/524)
Type 2 diabetes	29.7% (156/526)
BMI (n = 442)	27.01 ± 4.99
Dyslipidemia	20.8% (109/524)
Hypothyroidism	16.2% (85/524)
Psychiatric disorder	10.2% (53/521)
Previous alcohol use	19.2% (102/523)
HCV genotype
1A	37.0% (197)
1B	38.0% (202)
1 non-classified	3.5% (19)
2	0.8% (4)
3	20.1% (107)
4	0.4% (2)
5	0.2% (1)
HCV viral load (log IU/mL)	5.78 ± 0.75
Previous HCV treatment (n = 525)
None	46.3% (243)
Peg-IFN + RBV	46.1% (242)
Peg-IFN + PI	7.6% (40)
Liver fibrosis (Metavir classification)
F0/F1	8.8% (47)
F2	13.0% (69)
F3	20.7% (110)
F4	57.5% (306)
Liver-related complications (n = 306)
Ascites	30.3% (93)
Esophageal varices	72.0% (221)
Portal hypertensive bleeding	15.6% (48)
Hepatic encephalopathy	14.7% (45)
AST (U/L)	61.41 ± 45.06
ALT (U/L)	61.87 ± 58.29
Total bilirubin (mg/dL)	1.13 ± 1.08
Albumin (g/dL)	4.15 ± 2.64
Platelets (/mm3)	141.82 ± 77.21
INR	1.18 ± 0.23
Creatinine (mg/dL)	1.31 ± 1.96
Hemoglobin (g/dL)	13.73 ± 1.90
Alpha-fetoprotein (ng/mL)	23.59 ± 103.61
Child-Pugh classification (n = 306)
A	66.6% (204)
B or C	27.7% (85)
Non-classified	5.7% (17)
Child-Pugh Score (n = 289)	5.94 ± 1.54
MELD Score	10.17 ± 3.95

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMI: Body mass index; HCV: Hepatitis C virus; INR: International normalized ratio; MELD: Model for end-stage liver disease; Peg-IFN: Pegylated-interferon; PI: Protease inhibitor (boceprevir or telaprevir); RBV: Ribavirin.